Loading
institutionsInstitution
European Society of Gynaecological Oncology
Europe's gynaecologic oncology society, whose joint guidelines with ESTRO and ESP and its centre accreditation programme set European standards for ovarian, cervical and endometrial cancer care.
Also called: ESGO
Overview
Founded in 1983 and headquartered in Prague, ESGO represents gynaecologic oncologists and allied professionals across Europe and runs a biennial congress and a second scientific conference in the alternate years. Its guidelines with ESTRO and ESP on endometrial cancer introduced the molecular classification into routine care, its cervical cancer guidelines with ESTRO and ESP and its ovarian cancer guidelines with ESMO are widely used beyond Europe, and it accredits centres for advanced ovarian cancer surgery and for training through the ESGO Accreditation Programme and the European Network of Young Gynaecological Oncologists. ESGO publishes the International Journal of Gynecological Cancer with IGCS and works with ENGOT on trials and with patient advocacy through ENGAGe.
Location
Prague, CZ
Type
consortium
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#295 · 22 points (0 Newsweek + 0 NCI + 22 from 11 linked objects) · ranking
- ESGO Congress and State of the Art meetings
- Joint guidelines (with ESTRO, ESP, ESMO)
- Centre accreditation for ovarian cancer surgery
- ENGAGe patient advocacy network
Ane Gerda Eriksson
President-Elect
Gynaecological oncologyEndometrial cancerSurgical oncology
Oslo gynaecological oncology surgeon at the Norwegian Radium Hospital and President-Elect of ESGO.
Jalid Sehouli
President
Gynaecological oncologyOvarian cancerCytoreductive surgery
Berlin gynaecological oncologist and ESGO President, a leading ovarian cancer surgeon and trialist within the AGO study group.
Nicoletta Colombo
Director of Gynaecologic Oncology, European Institute of Oncology (IEO), Milan; Professor, University of Milan-Bicocca
Cervical cancerOvarian cancerImmunotherapy
Led KEYNOTE-826, which made pembrolizumab plus chemotherapy the first-line standard for recurrent or metastatic cervical cancer.
Anna Fagotti
Director, Gynecologic Oncology Unit, Gemelli; Professor, Università Cattolica
Ovarian cancer surgeryLaparoscopic assessmentCytoreductive surgery
Surgeon who developed the laparoscopic score for predicting whether ovarian cancer can be fully removed.
Giovanni Scambia
Scientific Director, Fondazione Policlinico Universitario A. Gemelli IRCCS; Professor of Gynaecology
Gynaecological oncologyOvarian cancer surgeryCervical cancer
Giovanni Scambia is a gynaecologic oncologist who leads research at the Gemelli hospital.
Similar pages
- PersonSébastien Armanet
Shares ARCAGY-GINECO, Endometrial cancer, Cervical cancer, Ovarian cancer.
- PersonThomas Herzog
Shares International journal of gynecological cancer, Endometrial cancer, Cervical cancer, Ovarian cancer.
- Key paperKEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (overall survival)
Shares Giovanni Scambia, Policlinico Universitario A. Gemelli, Brachytherapy, Cervical cancer.
- Key paperKEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (progression-free survival)
Shares Giovanni Scambia, Policlinico Universitario A. Gemelli, Brachytherapy, Cervical cancer.
- PersonKaren H. Lu
Shares Society of Gynecologic Oncology, Endometrial cancer, Ovarian cancer.
- PersonMatthew A. Powell
Shares Society of Gynecologic Oncology, Endometrial cancer, Ovarian cancer.
- TrialPAOLA-1 / ENGOT-ov25
Shares ARCAGY-GINECO, Society of Gynecologic Oncology, PARP inhibitors, Ovarian cancer.
- PersonNicole Concin
Shares International journal of gynecological cancer, Endometrial cancer, Ovarian cancer.